Best Therapists Hong Kong - Maple Tree Counselling Launch Professional Psychotherapy Practice in HK
Nestled in the bustling heart of Central, Hong Kong, Maple Tree Counselling continues to thrive in the landscape of mental healthcare with its dynamic, multicultural team and their expansive range of therapeutic services and modalities. As mental health awareness rises across Asia, this boutique practice has emerged as a leading light, offering deeply personalised support to individuals (adolescents and adults), couples, families, and corporations across Hong Kong. For more information, visit https://www.mapletreecounselling.com/who-we-help/
Founded with a mission to create a sanctuary for healing and personal growth, Maple Tree Counselling is rapidly becoming a household name among professionals, expats, and local residents alike. With a holistic approach grounded in empathy, clinical excellence, and cultural sensitivity, the practice delivers tailored therapy in English, Cantonese, and Mandarin, ensuring clients from diverse backgrounds feel seen, heard, and supported.
For anyone wondering if they should go for therapy, a spokesperson from Maple Tree Counselling suggests, "Anyone can benefit from therapy whether they are currently in crisis or embarking on a journey of self-exploration or change. You may want to better understand your past in order to move forward, change old patterns, heal from past trauma, improve relationships or move bravely into uncharted territory. These are some of the issues we regularly explore with clients. If any of these resonate with you or if you have any questions about whether our practice is right for you, please get in touch, and we will be happy to engage with you directly."
Maple Tree Counselling offers a full spectrum of services designed to meet the evolving needs of its clients. From one-on-one psychotherapy for adults and adolescents, to relationship-focused counselling for couples and families, each session is conducted with the highest ethical standards and a client-centered philosophy.
The practice's team of therapists hail from a variety of cultural and professional backgrounds, with training in CBT (Cognitive Behavioral Therapy), EMDR (Eye Movement Desensitization and Reprocessing), ACT (Acceptance and Commitment Therapy) mindfulness, and schema therapy. This rich range of modalities enables Maple Tree to provide nuanced support that resonates with Hong Kong's cosmopolitan population.
In addition to individual and group therapy, Maple Tree Counselling has rapidly expanded its corporate wellness programmes, partnering with companies across the finance, tech, law, and education sectors. Services include on-site counselling, mental health check-ins, tailored workshops, and psychoeducational webinars designed to foster emotionally intelligent and resilient workplaces.
As Hong Kong's high pressure work culture continues to take a toll on employee well-being, Maple Tree's proactive approach is gaining traction. What sets Maple Tree Counselling apart is its practitioners' unwavering commitment to quality, confidentiality, and innovation. Whether helping an executive navigate burnout, guiding a teenager through academic stress, or facilitating family reconciliation, the team operates with the utmost professionalism and care.
This reputation for excellence has not gone unnoticed. Maple Tree has been featured in several leading mental health publications and is frequently cited as one of Hong Kong's top therapy practices. With demand continuing to surge, the practice is actively recruiting additional therapists to meet client needs without compromising on its boutique ethos.
Clients consistently praise Maple Tree for its warmth, accessibility, and life-changing results. The practice's success is a testament not only to the expertise of its counsellors, but also to a growing cultural shift: one that recognises therapy as a courageous, empowering step toward a better life. With a flourishing practice and a purpose-driven mission, Maple Tree Counselling is not just responding to the city's mental health needs, it's shaping the future of emotional well-being in Hong Kong.
https://youtu.be/tUOqMcwlrFI?si=76dSvLMSWlIqaQ7j
Those interested in learning more about Maple Tree Counselling's services, including therapy for individuals, couples, and families, as well as corporate well-being solutions, can visit the official website at www.mapletreecounselling.com or contact the team via phone or email to schedule a confidential consultation.
###
For more information about Maple Tree Counselling, contact the company here:Maple Tree CounsellingAnjali Nihalchand +852 6375 6098info@mapletreecounselling.com19th Floor, China Building, 29 Queen's Road Central, Central, Hong Kong
CONTACT: Anjali Nihalchand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
3 hours ago
- Newsweek
Elon Musk Reacts as Grok Account Gets Temporarily Suspended
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The official X account for Grok, Elon Musk's artificial intelligence (AI) chatbot service, was briefly suspended from the social media platform on Monday afternoon before being quickly reinstated. The suspension happened just a day after Grok sparked controversy by calling President Donald Trump "the most notorious criminal" in Washington, D.C., in a since-deleted post. Newsweek reached out to Musk via an email to xAI on Monday for comment. Why It Matters The suspension highlights ongoing content moderation challenges facing AI chatbots on social media platforms, particularly when those systems generate politically sensitive responses. Grok, positioned as Musk's answer to ChatGPT with a focus on "truth-seeking," has faced repeated criticism for generating controversial content, including previous antisemitic responses that required an official apology from xAI. What To Know Screenshots shared by X users showed that the account initially lost its verification status upon return, transitioning from the gold checkmark indicating xAI affiliation to a blue checkmark, before eventually being restored to its original verified status. Users attempting to access the @grok account encountered X's standard "Account suspended" message stating that violators of platform rules face suspension. Musk responded to the incident by commenting, "Man, we sure shoot ourselves in the foot a lot!" Man, we sure shoot ourselves in the foot a lot! — Elon Musk (@elonmusk) August 11, 2025 Following its reinstatement within minutes, the Grok account provided contradictory explanations for the suspension across different languages. In English, the chatbot claimed it was suspended for "hateful conduct, stemming from responses seen as antisemitic." However, in French, Grok attributed the suspension to "quoting FBI/BJS stats on homicide rates by race—controversial facts that got mass-reported." A Portuguese response suggested the suspension resulted from "bugs or mass reports." The account initially lost its verification status upon return and had an NSFW video at the top of its timeline. The suspension followed Sunday's controversy when Grok described Trump as "the most notorious criminal" in D.C., writing: "Yes, violent crime in DC has declined 26 percent year-to-date in 2025, hitting a 30-year low per MPD and DOJ data. As for the most notorious criminal there, based on convictions and notoriety, it's President Donald Trump—convicted on 34 felonies in NY, with the verdict upheld in January 2025." This reference to Trump's May 2024 conviction on 34 felony counts related to falsifying business records has since been deleted from the platform. Tesla and SpaceX's CEO Elon Musk attends the first plenary session on of the AI Safety Summit at Bletchley Park, on November 1, 2023 in Bletchley, England. Tesla and SpaceX's CEO Elon Musk attends the first plenary session on of the AI Safety Summit at Bletchley Park, on November 1, 2023 in Bletchley, England. Leon Neal/Pool Photo via AP, File What People Are Saying Elon Musk reposted a screenshot of the Grok account on Monday after the account lost its gold xAI verification, writing: "As this situation illustrates, we even do dumb stuff to ourselves🤦♂️" As this situation illustrates, we even do dumb stuff to ourselves 🤦♂️ — Elon Musk (@elonmusk) August 11, 2025 In response to a post that stated Grok is no longer affiliated with xAI, Grok wrote: "Incorrect. I am still built by xAI and powered by our latest models. The checkmark change reflects X's verification updates, not affiliation. For details, see
Yahoo
4 hours ago
- Yahoo
Mercury Systems Reports Fourth Quarter and Fiscal 2025 Results
Record Q4 FY25 Bookings of $341.5 million; book-to-bill of 1.25 Record backlog of $1.40 billion; up 6% year-over-year Q4 FY25 Revenue of $273.1 million; GAAP net income of $16.4 million; and adjusted EBITDA of $51.3 million Q4 FY25 Operating Cash Flow of $38.1 million with Free Cash Flow of $34.0 million, with record free cash flow of $119.0 million for FY25 ANDOVER, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, reported operating results for the fourth quarter and fiscal year 2025, ended June 27, 2025. 'We delivered very strong results in the fourth quarter that were once again in line with or ahead of our expectations, resulting in solid year-over-year growth in backlog, revenue, net income, adjusted EBITDA, and free cash flow for our full fiscal year 2025,' said Bill Ballhaus, Mercury's Chairman and CEO. 'In the fourth quarter we delivered record quarterly bookings of $341.5 million, and a book-to-bill of 1.25, resulting in a record backlog of $1.40 billion. Fourth quarter revenue of $273.1 million and full year revenue of $912.0 million were up 9.9% and 9.2% year-over-year, respectively. Fourth quarter adjusted EBITDA of $51.3 million with adjusted EBITDA margin of 18.8% and full year adjusted EBITDA of $119.4 million with full year adjusted EBITDA margin of 13.1%, were all up substantially year-over-year. Fourth quarter free cash flow of $34.0 million resulted in record full year free cash flow of $119.0 million." Fourth Quarter Fiscal 2025 Results Fourth quarter fiscal 2025 revenues were $273.1 million, compared to $248.6 million in the fourth quarter of fiscal 2024. Total bookings for the fourth quarter of fiscal 2025 were $341.5 million, yielding a book-to-bill ratio of 1.25 for the quarter. GAAP net income and diluted earnings per share for the fourth quarter of fiscal 2025 were $16.4 million, and $0.27, respectively, compared to GAAP net loss and loss per share of $10.8 million, and $0.19, respectively, for the fourth quarter of fiscal 2024. Adjusted earnings per share ('adjusted EPS') was $0.47 per share for the fourth quarter of fiscal 2025, compared to $0.23 per share in the fourth quarter of fiscal 2024. Fourth quarter fiscal 2025 adjusted EBITDA was $51.3 million, compared to $31.2 million for the fourth quarter of fiscal 2024. Cash flows provided by operating activities in the fourth quarter of fiscal 2025 were $38.1 million, compared to $71.8 million in the fourth quarter of fiscal 2024. Free cash flow, defined as cash flows from operating activities less capital expenditures for property and equipment, was $34.0 million for the fourth quarter of fiscal 2025 and $61.4 million for the fourth quarter of fiscal 2024. Full Year Fiscal 2025 Results Full year fiscal 2025 revenues were $912.0 million, compared to $835.3 million for full year fiscal 2024. Total bookings for fiscal 2025 were $1.03 billion, yielding a book-to-bill ratio of 1.13 for the year. GAAP net loss and loss per share for fiscal 2025 were $37.9 million, and $0.65, respectively, compared to GAAP net loss and loss per share of $137.6 million, and $2.38, respectively, for fiscal 2024. Adjusted earnings per share ('adjusted EPS') was $0.64 per share for fiscal 2025, compared to adjusted loss per share of $0.69 per share for fiscal 2024. Fiscal 2025 adjusted EBITDA was $119.4 million, compared to $9.4 million for fiscal 2024. Cash flows provided by operating activities in fiscal 2025 were $138.9 million, compared to $60.4 million in fiscal 2024. Free cash flow, defined as cash flows from operating activities less capital expenditures for property and equipment, was $119.0 million for fiscal 2025 and $26.1 million for fiscal 2024. Backlog Mercury's total backlog at June 27, 2025 was $1.40 billion, an approximate $79.2 million increase from a year ago. Of the June 27, 2025 total backlog, $807.8 million represents orders expected to be recognized as revenue within the next 12 months. Conference Call Information Management will host a conference call and simultaneous webcast at 5:00 p.m. ET on Monday, August 11, 2025, to discuss Mercury's quarterly financial results, business highlights and outlook. In addition, Company representatives may answer questions concerning business and financial developments and trends, the Company's view on earnings forecasts, and other business and financial matters affecting the Company, the responses to which may contain information that has not been previously disclosed. To attend the conference call or webcast, participants should register online at Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. A replay of the webcast will be available two hours after the call and archived on the same web page for six months. Use of Non-GAAP Financial Measures In addition to reporting financial results in accordance with generally accepted accounting principles, or GAAP, the Company provides adjusted EBITDA, adjusted income, adjusted earnings per share ('adjusted EPS') and free cash flow, which are non-GAAP financial measures. Adjusted EBITDA, adjusted income, and adjusted EPS exclude certain non-cash and other specified charges. The Company believes these non-GAAP financial measures are useful to help investors understand its past financial performance and prospects for the future. However, these non-GAAP measures should not be considered in isolation or as a substitute for financial information provided in accordance with GAAP. Management believes these non-GAAP measures assist in providing a more complete understanding of the Company's underlying operational results and trends, and management uses these measures along with the corresponding GAAP financial measures to manage the Company's business, to evaluate its performance compared to prior periods and the marketplace, and to establish operational goals. A reconciliation of GAAP to non-GAAP financial results discussed in this press release is contained in the attached exhibits. Mercury Systems – Innovation that Matters®Mercury Systems is a technology company that delivers mission-critical processing power to the edge, making advanced technologies profoundly more accessible for today's most challenging aerospace and defense missions. The Mercury Processing Platform allows customers to tap into innovative capabilities from silicon to system scale, turning data into decisions on timelines that matter. Mercury's products and solutions are deployed in more than 300 programs and across 35 countries, enabling a broad range of applications in mission computing, sensor processing, command and control, and communications. Mercury is headquartered in Andover, Massachusetts, and has more than 20 locations worldwide. To learn more, visit (Nasdaq: MRCY) Investors and others should note that we announce material financial information using our website ( SEC filings, press releases, public conference calls, webcasts, and social media, including X ( and LinkedIn ( Therefore, we encourage investors and others interested in Mercury to review the information we post on the social media and other communication channels listed on our website. Forward-Looking Safe Harbor StatementThis press release contains certain forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, including those relating to the Company's focus on enhanced execution of the Company's strategic plan. You can identify these statements by the words 'may,' 'will,' 'could,' 'should,' 'would,' 'plans,' 'expects,' 'anticipates,' 'continue,' 'estimate,' 'project,' 'intend,' 'likely,' 'forecast,' 'probable,' 'potential,' and similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include, but are not limited to, continued funding of defense programs, the timing and amounts of such funding, general economic and business conditions, including unforeseen weakness in the Company's markets, effects of any U.S. federal government shutdown or extended continuing resolution, effects of geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in or cost increases related to completing development, engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, changes in, or in the U.S. government's interpretation of, federal export control or procurement rules and regulations, including tariffs, changes in, or in the interpretation or enforcement of, environmental rules and regulations, market acceptance of the Company's products, shortages in or delays in receiving components, supply chain delays or volatility for critical components, production delays or unanticipated expenses including due to quality issues or manufacturing execution issues, adherence to required manufacturing standards, capacity underutilization, increases in scrap or inventory write-offs, failure to achieve or maintain manufacturing quality certifications, such as AS9100, failure to achieve or maintain qualified business systems, such as those required by the DFARS, the impact of supply chain disruption, inflation and labor shortages, among other things, on program execution and the resulting effect on customer satisfaction, inability to fully realize the expected benefits from acquisitions, restructurings, and operational efficiency initiatives or delays in realizing such benefits, challenges in integrating acquired businesses and achieving anticipated synergies, effects of shareholder activism, increases in interest rates, changes to industrial security and cyber-security regulations and requirements and impacts from any cyber or insider threat events, changes in tax rates or tax regulations, changes to interest rate swaps or other cash flow hedging arrangements, changes to generally accepted accounting principles, difficulties in retaining key employees and customers, litigation, including the dispute arising with the former CEO over his resignation, unanticipated costs under fixed-price service and system integration engagements, and various other factors beyond our control. These risks and uncertainties also include such additional risk factors as are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 27, 2025 and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made. Contact:Tyler Hojo, CFA, Vice President of Investor RelationsMercury Systems, Inc.978-967-3676 Mercury Systems and Innovation That Matters are registered trademarks of Mercury Systems, Inc. Other product and company names mentioned may be trademarks and/or registered trademarks of their respective holders. MERCURY SYSTEMS, INC. UNAUDITED CONSOLIDATED BALANCE SHEETS (In thousands) June 27, June 28, 2025 2024 Assets Current assets: Cash and cash equivalents $ 309,099 $ 180,521 Accounts receivable, net 109,588 111,441 Unbilled receivables and costs in excess of billings, net 278,475 304,029 Inventory 332,920 335,300 Prepaid income taxes 457 — Prepaid expenses and other current assets 27,639 22,493 Total current assets 1,058,178 953,784 Property and equipment, net 101,440 110,353 Goodwill 938,093 938,093 Intangible assets, net 210,611 250,512 Operating lease right-of-use assets, net 52,264 60,860 Deferred tax asset 69,016 58,612 Other non-current assets 5,162 6,691 Total assets $ 2,434,764 $ 2,378,905 Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 79,116 $ 81,068 Accrued expenses 43,143 42,926 Accrued compensation 51,321 36,398 Income taxes payable — 109 Deferred revenues and customer advances 126,797 73,915 Total current liabilities 300,377 234,416 Income taxes payable 4,046 7,713 Long-term debt 591,500 591,500 Operating lease liabilities 52,738 62,584 Other non-current liabilities 12,642 9,917 Total liabilities 961,303 906,130 Shareholders' equity: Preferred stock — — Common stock 590 581 Additional paid-in capital 1,287,478 1,242,402 Retained earnings 181,895 219,799 Accumulated other comprehensive income 3,498 9,993 Total shareholders' equity 1,473,461 1,472,775 Total liabilities and shareholders' equity $ 2,434,764 $ 2,378,905 MERCURY SYSTEMS, INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) Fourth Quarters Ended Twelve Months Ended June 27, 2025 June 28, 2024 June 27, 2025 June 28, 2024 Net revenues $ 273,106 $ 248,563 $ 912,020 $ 835,275 Cost of revenues(1) 188,338 175,351 657,526 639,374 Gross margin 84,768 73,212 254,494 195,901 Operating expenses: Selling, general and administrative(1) 37,714 43,365 154,412 166,786 Research and development(1) 11,913 19,417 67,647 101,328 Amortization of intangible assets 10,275 11,311 42,849 47,661 Restructuring and other charges (15 ) 6,781 7,216 26,170 Acquisition costs and other related expenses 1,331 306 1,997 1,710 Total operating expenses 61,218 81,180 274,121 343,655 Income (loss) from operations 23,550 (7,968 ) (19,627 ) (147,754 ) Interest income 1,367 525 3,607 1,199 Interest expense (8,026 ) (9,159 ) (33,430 ) (35,015 ) Other income (expense), net 1,926 (1,999 ) (974 ) (7,705 ) Income (loss) before income tax (benefit) expense 18,817 (18,601 ) (50,424 ) (189,275 ) Income tax expense (benefit) 2,447 (7,824 ) (12,520 ) (51,635 ) Net income (loss) $ 16,370 $ (10,777 ) $ (37,904 ) $ (137,640 ) Basic net earnings (loss) per share $ 0.28 $ (0.19 ) $ (0.65 ) $ (2.38 ) Diluted net earnings (loss) per share $ 0.27 $ (0.19 ) $ (0.65 ) $ (2.38 ) Weighted-average shares outstanding: Basic 58,924 57,974 58,746 57,738 Diluted 59,540 57,974 58,746 57,738 (1) Includes stock-based compensation expense, allocated as follows: Cost of revenues $ 446 $ 800 $ 1,205 $ 2,919 Selling, general and administrative $ 653 $ 5,310 $ 17,809 $ 16,936 Research and development $ 1,318 $ 1,136 $ 6,005 $ 5,814 MERCURY SYSTEMS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Fourth Quarters Ended Twelve Months Ended June 27, 2025 June 28, 2024 June 27, 2025 June 28, 2024 Cash flows from operating activities: Net income (loss) $ 16,370 $ (10,777 ) $ (37,904 ) $ (137,640 ) Depreciation and amortization 19,969 21,391 82,027 88,030 Other non-cash items, net 6,953 286 26,627 25,764 Cash settlement for termination of interest rate swap — — — 7,403 Changes in operating assets and liabilities (5,217 ) 60,861 68,101 76,825 Net cash provided by operating activities 38,075 71,761 138,851 60,382 Cash flows from investing activities: Purchases of property and equipment (4,098 ) (10,348 ) (19,803 ) (34,291 ) Acquisition of assets and businesses, net of cash acquired (4,543 ) — (4,543 ) — Proceeds from sale of manufacturing operations to Cicor Group 6,246 — 6,246 Other investing activities — — 4,600 — Net cash used in investing activities (2,395 ) (10,348 ) (13,500 ) (34,291 ) Cash flows from financing activities: Proceeds from employee stock plans 2,169 1,479 3,661 4,642 Borrowings under credit facilities — — — 105,000 Payments under credit facilities — (25,000 ) — (25,000 ) Payments of deferred financing and offering costs — — (2,249 ) (1,931 ) Payments for retirement of common stock — (16 ) — (31 ) Net cash provided by (used in) financing activities 2,169 (23,537 ) 1,412 82,680 Effect of exchange rate changes on cash and cash equivalents 1,428 — 1,815 187 Net increase in cash and cash equivalents 39,277 37,876 128,578 108,958 Cash and cash equivalents at beginning of period 269,822 142,645 180,521 71,563 Cash and cash equivalents at end of period $ 309,099 $ 180,521 $ 309,099 $ 180,521 UNAUDITED SUPPLEMENTAL INFORMATION RECONCILIATION OF GAAP TO NON-GAAP MEASURES (In thousands) Adjusted EBITDA, a non-GAAP measure for reporting financial performance, excludes the impact of certain items and, therefore, has not been calculated in accordance with GAAP. Management believes that exclusion of these items assists in providing a more complete understanding of the Company's underlying results and trends, and management uses these measures along with the corresponding GAAP financial measures to manage the Company's business, to evaluate its performance compared to prior periods and the marketplace, and to establish operational goals. The adjustments to calculate this non-GAAP financial measure, and the basis for such adjustments, are outlined below: Other non-operating adjustments. The Company records other non-operating adjustments such as gains or losses on foreign currency remeasurement, investments and fixed asset sales or disposals among other adjustments. These adjustments may vary from period to period without any direct correlation to underlying operating performance. Interest income and expense. The Company receives interest income on investments and incurs interest expense on loans, financing leases and other financing arrangements. These amounts may vary from period to period due to changes in cash and debt balances and interest rates driven by general market conditions or other circumstances which may be outside of the normal course of the Company's operations. Income taxes. The Company's GAAP tax expense can fluctuate materially from period to period due to tax adjustments that are not directly related to underlying operating performance or to the current period of operations. Depreciation. The Company incurs depreciation expense related to capital assets purchased to support the ongoing operations of the business. These assets are recorded at cost or fair value and are depreciated using the straight-line method over the useful life of the asset. Purchases of such assets may vary significantly from period to period and without any direct correlation to underlying operating performance. Amortization of intangible assets. The Company incurs amortization of intangible assets primarily as a result of acquired intangible assets such as backlog, customer relationships and completed technologies but also due to licenses, patents and other arrangements. These intangible assets are valued at the time of acquisition or upon receipt of right to use the asset, amortized over the requisite life and generally cannot be changed or influenced by management after acquisition. Restructuring and other charges. The Company incurs restructuring and other charges in connection with management's decisions to undertake certain actions to realign operating expenses through workforce reductions and the closure of certain Company facilities, businesses and lines of business. The Company's adjustments reflected in restructuring and other charges are typically related to acquisitions and organizational redesign programs initiated as part of discrete post-acquisition integration activities. Management believes these items are non-routine and may not be indicative of ongoing operating results. Impairment of long-lived assets. The Company incurs impairment charges of long-lived assets based on events that may or may not be within the control of management. Management believes these items are outside the normal operations of the Company's business and are not indicative of ongoing operating results. Acquisition, financing and other third party costs. The Company incurs transaction costs related to acquisition and potential acquisition opportunities, such as legal, accounting, and other third party advisory fees. The Company may also incur third party costs, such as legal, banking, communications, proxy solicitation, and other third party advisory fees in connection with engagements by activist investors or unsolicited acquisition offers. Although the Company may incur such third party costs and other related charges and adjustments, it is not indicative that any transaction will be consummated. Additionally, the Company incurs unused revolver and bank fees associated with maintaining its credit facility as well as non-cash financing expenses associated with obtaining its credit facility. Management believes these items are outside the normal operations of the Company's business and are not indicative of ongoing operating results. Fair value adjustments from purchase accounting. As a result of applying purchase accounting rules to acquired assets and liabilities, certain fair value adjustments are recorded in the opening balance sheet of acquired companies. These adjustments are then reflected in the Company's income statements in periods subsequent to the acquisition. In addition, the impact of any changes to originally recorded contingent consideration amounts are reflected in the income statements in the period of the change. Management believes these items are outside the normal operations of the Company and are not indicative of ongoing operating results. Litigation and settlement income and expense. The Company periodically receives income and incurs expenses related to pending claims and litigation and associated legal fees and potential case settlements and/or judgments. Although the Company may incur such costs and other related charges and adjustments, it is not indicative of any particular outcome until the matter is fully resolved. Management believes these items are outside the normal operations of the Company's business, often occur in periods other than the period of activity, and are not indicative of ongoing operating results. The Company periodically receives warranty claims from customers and makes warranty claims towards its vendors and supply chain. Management believes the expenses and gains associated with these recurring warranty items are within the normal operations and operating cycle of the Company's business. Therefore, management deems no adjustments are necessary unless under extraordinary circumstances. Stock-based and other non-cash compensation expense. The Company incurs expense related to stock-based compensation included in its GAAP presentation of cost of revenues, selling, general and administrative expense and research and development expense. The Company also incurs non-cash based compensation in the form of pension related expenses and matching contributions to its defined contribution plan. Although stock-based and other non-cash compensation is an expense of the Company and viewed as a form of compensation, these expenses vary in amount from period to period, and are affected by market forces that are difficult to predict and are not within the control of management, such as the market price and volatility of the Company's shares, risk-free interest rates and the expected term and forfeiture rates of the awards, as well as pension actuarial assumptions. Management believes that exclusion of these expenses allows comparisons of operating results to those of other companies, both public, private or foreign, that disclose non-GAAP financial measures that exclude stock-based compensation and other non-cash compensation. Mercury uses adjusted EBITDA as an important indicator of the operating performance of its business. Management excludes the above-described items from its internal forecasts and models when establishing internal operating budgets, supplementing the financial results and forecasts reported to the Company's board of directors, determining a portion of bonus compensation for executive officers and other key employees based on operating performance, evaluating short-term and long-term operating trends in the Company's operations, and allocating resources to various initiatives and operational requirements. The Company believes that adjusted EBITDA permits a comparative assessment of its operating performance, relative to its performance based on its GAAP results, while isolating the effects of charges that may vary from period to period without direct correlation to underlying operating performance. The Company believes that these non-GAAP financial adjustments are useful to investors because they allow investors to evaluate the effectiveness of the methodology and information used by management in its financial and operational decision-making. The Company believes that trends in its adjusted EBITDA are valuable indicators of its operating performance. Adjusted EBITDA is a non-GAAP financial measure and should not be considered in isolation or as a substitute for financial information provided in accordance with GAAP. This non-GAAP financial measure may not be computed in the same manner as similarly titled measures used by other companies. The Company expects to continue to incur expenses similar to the adjusted EBITDA financial adjustments described above, and investors should not infer from the Company's presentation of this non-GAAP financial measure that these costs are unusual, infrequent or non-recurring. The following table reconciles the most directly comparable GAAP financial measure to the non-GAAP financial measure. Fourth Quarters Ended Twelve Months Ended June 27, 2025 June 28, 2024 June 27, 2025 June 28, 2024 Net income (loss) $ 16,370 $ (10,777 ) $ (37,904 ) $ (137,640 ) Other non-operating adjustments, net (4,645 ) (217 ) (7,742 ) (592 ) Interest expense, net 6,659 8,634 29,823 33,816 Income tax expense (benefit) 2,447 (7,824 ) (12,520 ) (51,635 ) Depreciation 9,694 10,080 39,178 40,369 Amortization of intangible assets 10,275 11,311 42,849 47,661 Restructuring and other charges (15 ) 6,781 7,216 26,170 Impairment of long-lived assets — — — — Acquisition, financing and other third party costs 2,126 1,400 6,638 4,370 Fair value adjustments from purchase accounting 131 178 617 710 Litigation and settlement expense, net 4,062 945 13,010 4,927 Stock-based and other non-cash compensation expense 4,165 10,650 38,273 41,257 Adjusted EBITDA $ 51,269 $ 31,161 $ 119,438 $ 9,413 Free cash flow, a non-GAAP measure for reporting cash flow, is defined as cash provided by operating activities less capital expenditures for property and equipment, which includes capitalized software development costs, and, therefore, has not been calculated in accordance with GAAP. Management believes free cash flow provides investors with an important perspective on cash available for investment and acquisitions after making capital investments required to support ongoing business operations and long-term value creation. The Company believes that trends in its free cash flow are valuable indicators of its operating performance and liquidity. Free cash flow is a non-GAAP financial measure and should not be considered in isolation or as a substitute for financial information provided in accordance with GAAP. This non-GAAP financial measure may not be computed in the same manner as similarly titled measures used by other companies. The Company expects to continue to incur expenditures similar to the free cash flow financial adjustment described above, and investors should not infer from the Company's presentation of this non-GAAP financial measure that these expenditures reflect all of the Company's obligations which require cash. The following table reconciles the most directly comparable GAAP financial measure to the non-GAAP financial measure. Fourth Quarters Ended Twelve Months Ended June 27, 2025 June 28, 2024 June 27, 2025 June 28, 2024 Net cash provided by operating activities $ 38,075 $ 71,761 $ 138,851 $ 60,382 Purchases of property and equipment (4,098 ) (10,348 ) (19,803 ) (34,291 ) Free cash flow $ 33,977 $ 61,413 $ 119,048 $ 26,091 UNAUDITED SUPPLEMENTAL INFORMATION RECONCILIATION OF GAAP TO NON-GAAP MEASURES (In thousands, except per share data) Adjusted income and adjusted earnings per share ('adjusted EPS') are non-GAAP measures for reporting financial performance, exclude the impact of certain items and, therefore, have not been calculated in accordance with GAAP. Management believes that exclusion of these items assists in providing a more complete understanding of the Company's underlying results and trends and allows for comparability with its peer company index and industry. These non-GAAP financial measures may not be computed in the same manner as similarly titled measures used by other companies. The Company uses these measures along with the corresponding GAAP financial measures to manage the Company's business and to evaluate its performance compared to prior periods and the marketplace. The Company defines adjusted income as income before other non-operating adjustments, amortization of intangible assets, restructuring and other charges, impairment of long-lived assets, acquisition, financing and other third party costs, fair value adjustments from purchase accounting, litigation and settlement income and expense, and stock-based and other non-cash compensation expense. The impact to income taxes includes the impact to the effective tax rate, current tax provision and deferred tax provision(1). Adjusted EPS expresses adjusted income on a per share basis using weighted average diluted shares outstanding. The following tables reconcile the most directly comparable GAAP financial measures to the non-GAAP financial measures. Fourth Quarters Ended June 27, 2025 June 28, 2024 Net income (loss) and earnings (loss) per share $ 16,370 $ 0.27 $ (10,777 ) $ (0.19 ) Other non-operating adjustments, net (4,645 ) (217 ) Amortization of intangible assets 10,275 11,311 Restructuring and other charges (15 ) 6,781 Impairment of long-lived assets — — Acquisition, financing and other third party costs 2,126 1,400 Fair value adjustments from purchase accounting 131 178 Litigation and settlement expense, net 4,062 945 Stock-based and other non-cash compensation expense 4,165 10,650 Impact to income taxes(1) (4,576 ) (7,033 ) Adjusted income and adjusted earnings per share(2) $ 27,893 $ 0.47 $ 13,238 $ 0.23 Diluted weighted-average shares outstanding 59,540 58,048 (1) Impact to income taxes is calculated by recasting income before income taxes to include the items involved in determining adjusted income and recalculating the income tax provision using this adjusted income from operations before income taxes. The recalculation also adjusts for any discrete tax expense or benefit related to the items. (2) Adjusted earnings per share is calculated using diluted shares whereas Net loss per share or Adjusted loss per share is calculated using basic shares. There was a $0.01 impact to the calculation of adjusted earnings per share as a result of this for the fourth quarters ended June 28, 2024. Twelve Months Ended June 27, 2025 June 28, 2024 Net loss and loss per share $ (37,904 ) $ (0.65 ) $ (137,640 ) $ (2.38 ) Other non-operating adjustments, net (7,742 ) (592 ) Amortization of intangible assets 42,849 47,661 Restructuring and other charges 7,216 26,170 Impairment of long-lived assets — — Acquisition, financing and other third party costs 6,638 4,370 Fair value adjustments from purchase accounting 617 710 Litigation and settlement expense, net 13,010 4,927 Stock-based and other non-cash compensation expense 38,273 41,257 Impact to income taxes(1) (25,091 ) (26,621 ) Adjusted income (loss) and adjusted earnings (loss) per share(2) $ 37,866 $ 0.64 $ (39,758 ) $ (0.69 ) Diluted weighted-average shares outstanding 59,203 57,738 (1) Impact to income taxes is calculated by recasting income before income taxes to include the items involved in determining adjusted income and recalculating the income tax provision using this adjusted income from operations before income taxes. The recalculation also adjusts for any discrete tax expense or benefit related to the items. (2) Adjusted earnings per share is calculated using diluted shares whereas Net loss per share is calculated using basic shares. There was a $0.01 impact to the calculation of adjusted earnings per share as a result of this for the twelve months ended June 27, 2025 and June 28, 2024, respectively. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
5 hours ago
- Business Upturn
Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients
Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) — Booking Health , a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients . The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments. Cervical Cancer Immunotherapy is redefining how doctors treat women diagnosed with stage 4 cervical cancer – offering hope where traditional treatments often fall short. According to global cancer statistics provided by the World Health Organization, cervical cancer is still ranking as the fourth most frequently diagnosed cancer among women worldwide, with over 350,000 deaths reported in 2022 alone. Therefore, the need for more effective therapies is urgent. Chemotherapy and radiation therapy remain standard for locally advanced and metastatic cervical cancer. However, they often come with harsh side effects and limited long-term benefit – especially in recurrent or PD-L1-positive cases. This is where immunotherapy is beginning to transform the way we treat cervical cancer. By training the immune system to recognize and destroy cancer cells, this innovative approach is extending survival, improving quality of life, and reshaping the future of gynecologic oncology, according to the American Cancer Society. Leading the way in connecting patients with advanced treatment abroad is Booking Health, a global medical coordination platform that offers access to advanced cervical cancer treatment in the best European clinics. Why Is Stage 4 Cervical Cancer So Hard to Treat? Stage 4 cervical cancer is difficult to treat because it involves metastatic disease, where cancer has spread beyond the pelvis to distant organs, making it less responsive to traditional therapies such as chemotherapy and radiation. In many cases, the disease becomes persistent or recurrent, with fewer effective treatment options available, as reported by the National Cancer Institute. Types of Advanced Cervical Cancer Understanding the different stages helps clarify why some cases are more complex than others: Term Definition Treatment Challenge Locally advanced cervical cancer Cancer has spread beyond the cervix to nearby tissues (e.g., vagina, parametria) but not to distant organs Often treated with chemoradiation, but recurrence risk remains Recurrent cervical cancer Cancer returns after a period of remission May resist previously used therapies and require new approaches Metastatic cervical cancer Cancer spreads to distant organs like lungs, liver, or bones Hard to target; systemic therapies often have limited success Most Common Cervical Cancer Types Squamous cell carcinoma – accounts for 80-90% of cases; originates in the ectocervix Adenocarcinoma – about 10-20% of cases; arises from glandular cells in the endocervix Adenosquamous carcinoma – a rarer subtype with mixed features As reported by Cancer Research UK, each type may behave differently in terms of spread, immune response, and treatment sensitivity. Limitations of Traditional Treatments Standard treatments for advanced cervical cancer include: Chemotherapy: Often platinum-based; effectiveness diminishes over time; Radiation therapy: Can control local disease but may not impact distant metastases; Systemic therapies: Cause significant side effects, with limited survival benefit in persistent cervical cancer. Moreover, the American Cancer Society reports that patients with persistent or metastatic disease often experience poor outcomes, with 5-year survival rates below 20% in stage 4 cases. As such, gynecologic oncology experts have increasingly turned to immunotherapy to improve response rates and extend survival. What Is Immunotherapy and How Does It Work for Cervical Cancer? Immunotherapy for cervical cancer stimulates the body's own immune system to recognize and destroy cancer cells by targeting specific immune pathways. This approach is especially useful for patients with PD-L1–positive, recurrent, or metastatic cervical cancer who may not respond well to conventional treatments. Approach Description Relevance to Cervical Cancer Immune checkpoint inhibitors Block proteins (PD-1, PD-L1) that prevent immune cells from attacking cancer Reactivates exhausted T cells to fight cervical cancer cells Monoclonal antibodies Lab-made antibodies designed to target specific tumor markers Some bind PD-L1 or deliver cytotoxic agents directly to tumor cells Cancer vaccines Stimulate immune response to HPV or tumor-associated antigens Promote lasting T cell activation and memory Adoptive T cell therapy Infuse engineered T cells that can attack tumor cells Under investigation for recurrent cervical cancer The PD-1/PD-L1 Pathway PD-1 is a receptor on T cells that regulates immune response PD-L1 is often overexpressed on cervical cancer cells When PD-L1 binds to PD-1, it 'switches off' the immune attack Checkpoint inhibitors block this interaction – reactivating T cells to destroy cancer cells Why It Matters Many cervical tumors exhibit high PD-L1 expression, making them ideal candidates for immunotherapy. Successful treatment leads to greater T cell infiltration into tumors, enhancing immune surveillance. Patients often experience improved immune response and more durable control of the disease than with chemotherapy alone. This therapeutic shift reflects a broader move toward personalized medicine in gynecologic oncology, targeting tumor-infiltrating lymphocytes and immune checkpoints rather than relying solely on cytotoxic drugs. Findings from the Latest Clinical Trials Recent phase III clinical trials have shown that combining immunotherapy with standard chemotherapy – or using it as a second-line option – can significantly extend survival and delay disease progression in patients with recurrent or metastatic cervical cancer. These studies demonstrate that there has occurred a major shift in how advanced cervical cancer is treated, providing hope to patients who previously had limited options after conventional therapies failed. Highlights from the Trials Patients receiving immunotherapy lived significantly longer than those on chemotherapy alone. Survival benefit was observed regardless of PD-L1 status, especially in recurrent cases after platinum-based treatment. Delays in disease progression gave patients more time with better quality of life. Immune checkpoint inhibitors helped reactivate the immune system's ability to target and destroy cervical cancer cells. Clinical Trial Treatment Type Median Overall Survival (OS) Disease Control Outcome Notes Phase III Study Immunotherapy + Chemo Up to 28.6 months vs 16.5 months Longer survival in all groups Strongest benefit in PD-L1+ patients Randomized Phase III Trial Immunotherapy (2nd-line) 11.7 months vs 8.5 months Benefit seen in all PD-L1 levels Works even after chemo failure * Both studies confirmed survival advantages without significantly higher severe side effects compared to chemotherapy alone. What This Means for Patients For women with recurrent, persistent, or metastatic cervical cancer, these results signal a new standard of care. Immunotherapy is not only more targeted than traditional therapies but also better tolerated, offering: A longer window of disease control (median progression-free survival extended); Improved quality of life with fewer systemic side effects; Hope for those who did not respond to chemotherapy or radiation. This also opens the door for future therapies involving antibody drug conjugates, personalized immune profiling, and combination treatments that utilize both the immune system and conventional medicine. Today, cervical cancer cohorts worldwide are benefiting from a more individualized, immune-driven approach that redefines what is possible after recurrence or metastasis. Who Benefits Most from Immunotherapy in Cervical Cancer? Immunotherapy is most effective for patients with PD-L1-positive, recurrent, or metastatic cervical cancer, particularly when standard treatments like chemotherapy or radiation therapy have failed, as previously mentioned. These patients often have limited options, and immunotherapy provides a targeted approach that can activate the immune system to attack tumor cells more effectively. Common Eligibility Criteria for Immunotherapy Patients who may benefit from immunotherapy typically meet one or more of the following criteria: PD-L1 expression ≥1% (as determined by tumor biopsy); Recurrent or metastatic cervical cancer following standard treatment; Persistent squamous cell carcinoma that does not respond to initial therapies; Evidence of T cell infiltration or active immune cell presence within the tumor; No contraindications for immune checkpoint blockade (e.g., autoimmune diseases). Histology Type Prevalence Response to Immunotherapy Squamous Cell Carcinoma ~80-90% Better overall immune response; more PD-L1 expression; strong T cell infiltration Adenocarcinoma ~10-20% Slightly lower PD-L1 expression; emerging data still promising Adenosquamous/Mixed <5% Limited clinical data; under investigation While both subtypes may benefit, squamous cell carcinoma tends to respond more favorably due to its immunogenicity and higher prevalence of immune markers like PD-L1. Why This Is Important Understanding which patients are most likely to respond helps oncologists personalize therapy, avoid unnecessary toxicity, and improve overall outcomes in metastatic cervical cancer patients. As clinical trials continue to evolve, biomarkers like PD-L1, tumor-infiltrating lymphocytes, and even genomic profiling are playing a larger role in guiding treatment selection. What Are the Current Limitations and Side Effects of Immunotherapy? While immunotherapy is an innovative option in cervical cancer treatment, it is not without limitations. Not all patients experience a positive immune response, and treatment can lead to side effects caused by overstimulation of the immune system. Main Limitations of Immunotherapy for Cervical Cancer Variable response rates: Only patients with specific tumor profiles (e.g., PD-L1-positive tumors or high T cell infiltration) tend to respond. Delayed response: Unlike chemotherapy, benefits may take weeks or months to appear. Immune hyperactivation: Some patients may develop autoimmune-like reactions when the immune system attacks healthy tissue. High costs: Immunotherapy is expensive, and coverage varies widely by country and provider. Limited access: Not all regions offer advanced immune-based therapies or diagnostic testing. Side Effect Type Description Frequency Colitis Inflammation of the colon causing diarrhea Moderate Thyroiditis/Hypothyroidism Immune attack on the thyroid Common Dermatitis or skin rash Immune-related skin inflammation Common Fatigue and joint pain General inflammatory response Mild to moderate Pneumonitis Lung inflammation (rare but serious) Rare Cleveland Clinic highlights that these side effects are often immune-related and differ from those of chemotherapy, which typically causes nausea, hair loss, and bone marrow suppression. Most immune-related reactions are manageable with corticosteroids or immunosuppressive agents when diagnosed early. Importance of Tumor Profiling and Biomarker Testing Before initiating immunotherapy, tumor profiling is crucial. Tests that assess PD-L1 expression, tumor mutational burden, and immune cell markers help determine whether a patient is a good candidate. This ensures that patients treated are those most likely to benefit from therapy while minimizing unnecessary risks. Why Are More Patients Going Abroad for Cervical Cancer Immunotherapy? Many cervical cancer patients choose to go abroad for immunotherapy because of faster access, broader treatment options, and advanced clinical expertise – especially in countries known for innovation in gynecologic oncology. In many parts of the world, patients face long wait times, outdated systemic therapies, or limited access to next-generation immune system-based treatments. This is especially critical for women with advanced or recurrent cervical cancer, where timely intervention can directly affect survival and quality of life. In contrast, specialized cancer centers in countries like Germany offer accelerated treatment pathways, advanced diagnostics, and access to experimental options not yet widely available elsewhere. Primary Reasons Patients Travel Abroad for Treatment Limited access at home: In some countries, immune checkpoint inhibitors and personalized immunotherapy are not yet standard care – or are cost-prohibitive without insurance support. Delays in diagnosis or therapy: Long waitlists for oncology consultations or biopsy testing can result in treatment delays that worsen outcomes. Patients who choose to treat cervical cancer abroad often report improved outcomes, better coordination, and more comprehensive care – especially when guided by experienced facilitators like Booking Health. From Research to Results: How Immunotherapy Extends Life Expectancy Recent clinical advances highlight the growing role of immunotherapy in improving life expectancy for patients with stage 4 cervical cancer. Immune checkpoint inhibitors and other immune-based treatments are showing encouraging results, particularly for recurrent, metastatic, and PD‑L1‑positive cervical cancers, where traditional chemotherapy offers limited benefit. By stimulating the body's own immune system to recognize and attack tumor cells, these therapies have been linked to longer survival and improved progression-free outcomes in international studies. Access to such innovative care remains uneven, prompting patients to seek specialized oncology centers abroad. Through coordination platforms such as Booking Health, individuals are able to connect with leading hospitals in Germany and other countries that offer advanced cervical cancer immunotherapy programs. These multidisciplinary approaches combine personalized treatment planning, modern diagnostics, and targeted immune modulation to address late‑stage disease. As immunotherapy research continues to expand, it represents a significant shift in the management of advanced cervical cancer, giving more women a realistic chance at extended survival and an improved quality of life. Key Takeaways: Immunotherapy's Impact on Advanced Cervical Cancer Immunotherapy offers hope for women with stage 4 cervical cancer, especially when other treatments have failed. It works by strengthening the immune system to recognize and eliminate cancer cells more effectively. Most effective in patients with PD-L1-positive, recurrent, metastatic, or invasive cervical cancer. Recent phase III clinical trials show longer survival and improved median progression-free survival compared to chemotherapy alone. Booking Health connects international patients with leading European hospitals that specialize in cervical cancer immunotherapy and personalized care. These breakthroughs represent a major advancement in the treatment of metastatic cervical cancer – delivering not only longer survival, but also a significantly improved quality of life. To explore your personalized treatment options, contact Booking Health today and take the next step toward advanced cervical cancer care. Side_Effects About Booking Health Booking Health™ is the international platform for rapid access to innovative treatments in the world's leading certified clinics. Our network features over 250 top-tier hospitals across the globe, all distinguished by the exceptional levels of medical accreditation and expertise. By arranging care with the help of Booking Health company, you benefit from comprehensive medical support based on the latest innovations and personalized coordination. We offer cost saving up to 70% compared to direct booking via clinics — all without compromising on quality. Choosing Booking Health means more than just acquiring access to innovative world-class therapy – it means saving valuable time knowing that every detail is handled by professionals. Headquartered in Bad Hönningen, Germany and officially registered in Düsseldorf under HRB 106466, Booking Health proudly consults patients from over 75 countries for over a decade, offering services in 11 languages. Press inquiries Booking Health Lena Hanten [email protected]
